"Quad" pill approval extends Gilead's string of one-tab offerings
August 28 2012
The agency approved the four-in-one HIV/AIDS treatment for new patients. The drug could cost patients $28,500 a year.
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.